Showing 5291-5300 of 7761 results for "".
- Promoting Pigmentation and Preventing Relapses Highlighted as Keys in Vitiligo Treatmenthttps://practicaldermatology.com/news/Promoting-Pigmentation-Preventing-Relapses-Highlighted-Keys-Vitiligo-Treatment/2471550/The way practitioners diagnose and manage vitiligo patients continues to advance with recent discoveries in the pathogenesis, risk factors, and features of the disease activity. At the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, one discussion focused on pattern
- Exosomes for Hair Regrowth: Tech with Potentialhttps://practicaldermatology.com/news/exosomes-for-hair-regrowth-tech-with-potential/2471533/
- Beyond the Surface: Updates in Itch Treatmenthttps://practicaldermatology.com/news/beyond-the-surface-updates-in-itch-treatment/2471285/
- Bill Collection Made Tougher by Recent Changes in Credit Reportinghttps://practicaldermatology.com/news/Bill-Collection-Made-Tougher-Recent-Changes-Credit-Reporting/2471259/Americans owe $220 billion in medical debt,1 and the most effective method for collecting money could soon cease to be an option. Mark Nestor, MD, PhD, highlighted this issue during a presentation at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “Ba
- Weight-Loss Drugs Highlighted as 'Easy' Option to Improve PsO Therapieshttps://practicaldermatology.com/news/Weight-Loss-Drugs-Highlighted-Easy-Option-Improve-PsO-Therapies/2471215/Any dermatologist not prescribing weight-loss drugs for psoriasis patients who are obese likely will be soon, according to Mark Lebwohl, MD. Dr. Lebwohl, speaking at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii, highlighted data indicating an association between como
- Study: Safety Signals Emerge for IL-23 and IL-12/23 Inhibitors in Psoriasis Treatmenthttps://practicaldermatology.com/news/safety-signals-emerge-for-il-23-and-il-1223-inhibitors-in-psoriasis-treatment/2470971/A new analysis of psoriasis patients indicates an emergence of new safety signals associated with interleukin-23 (IL-23) inhibitors and the IL-12/23 inhibitor ustekinumab. Researchers on the study analyzed 41.4 million adverse event (AE) reports from the FDA Adverse Event Reporting System
- GW SMHS Teledermatology Program Receives Renewed Fundinghttps://practicaldermatology.com/news/gw-smhs-teledermatology-program-receives-renewed-funding/2468756/The George Washington University School of Medicine and Health Sciences Department of Dermatology, in collaboration with the Pennsylvania Avenue Baptist Church and the National Psoriasis Foundation (NPF), announced a renewed funding commitment of $350,000 from Johnson & Johnson in support of
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- Long-Term Mortality in Epidermal Necrolysis Influenced by In-Hospital Complicationshttps://practicaldermatology.com/news/long-term-mortality-epidermal-necrolysis-influenced-hospital-complications/2468372/Epidermal necrolysis (EN) is associated with high in-hospital and post-discharge mortality rates, with comorbidities playing a significant role in outcomes. Researchers for the recent cohort study used French Health System data to characterize mortality and sequelae associated with EN, whi
- New Algorithm Helps Detect Aggressive Basal Cell Carcinoma for Optimal Treatmenthttps://practicaldermatology.com/news/new-algorithm-helps-detect-aggressive-basal-cell-carcinoma-optimal-treatment/2467648/An algorithm can help healthcare professionals recognize which patients have a highly aggressive form of basal cell carcinoma (BCC) of the face. These are the findings of a study conducted at the University of Gothenburg. If more BCCs are correctly identified as high-risk, the patients can direct